Hypertension Diagnostics Stock Performance
| HDII Stock | USD 0.0001 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Hypertension Diagnostics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Hypertension Diagnostics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong forward indicators, Hypertension Diagnostics is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 285.4 K | |
| Total Cashflows From Investing Activities | -2111.00 |
Hypertension |
Hypertension Diagnostics Relative Risk vs. Return Landscape
If you would invest 0.01 in Hypertension Diagnostics on October 8, 2025 and sell it today you would earn a total of 0.00 from holding Hypertension Diagnostics or generate 0.0% return on investment over 90 days. Hypertension Diagnostics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Hypertension, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Hypertension Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Hypertension Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Hypertension Diagnostics, and traders can use it to determine the average amount a Hypertension Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| HDII |
Based on monthly moving average Hypertension Diagnostics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Hypertension Diagnostics by adding Hypertension Diagnostics to a well-diversified portfolio.
Hypertension Diagnostics Fundamentals Growth
Hypertension Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Hypertension Diagnostics, and Hypertension Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hypertension Pink Sheet performance.
| Return On Asset | 3.0E-4 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | 0.0002 % | |||
| Current Valuation | 5.26 M | |||
| Shares Outstanding | 52.39 M | |||
| Price To Earning | (0.03) X | |||
| Price To Sales | 0.15 X | |||
| Revenue | 3.79 M | |||
| EBITDA | 72.29 K | |||
| Cash And Equivalents | 5.66 K | |||
| Total Debt | 4.69 M | |||
| Book Value Per Share | (0.09) X | |||
| Cash Flow From Operations | (389.28 K) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 1.28 M | |||
| Retained Earnings | (30.68 M) | |||
| Current Asset | 277 K | |||
| Current Liabilities | 1.13 M | |||
About Hypertension Diagnostics Performance
By evaluating Hypertension Diagnostics' fundamental ratios, stakeholders can gain valuable insights into Hypertension Diagnostics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Hypertension Diagnostics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hypertension Diagnostics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Hypertension Diagnostics, Inc. designs, develops, manufactures, and markets proprietary noninvasive medical devices that detect subtle changes in the elasticity of arteries in the United States and internationally. Hypertension Diagnostics, Inc. was founded in 1988 and is based in Richmond Hill, Canada. Hypertension Diag operates under Shell Companies classification in the United States and is traded on OTC Exchange.Things to note about Hypertension Diagnostics performance evaluation
Checking the ongoing alerts about Hypertension Diagnostics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Hypertension Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hypertension Diagnostics generated a negative expected return over the last 90 days | |
| Hypertension Diagnostics has some characteristics of a very speculative penny stock | |
| Hypertension Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| Hypertension Diagnostics currently holds 4.69 M in liabilities. Hypertension Diagnostics has a current ratio of 0.51, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Hypertension Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, Hypertension Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hypertension Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hypertension to invest in growth at high rates of return. When we think about Hypertension Diagnostics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 3.79 M. Net Loss for the year was (125.39 K) with profit before overhead, payroll, taxes, and interest of 954.47 K. | |
| Hypertension Diagnostics currently holds about 5.66 K in cash with (389.28 K) of positive cash flow from operations. |
- Analyzing Hypertension Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hypertension Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Hypertension Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hypertension Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hypertension Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hypertension Diagnostics' pink sheet. These opinions can provide insight into Hypertension Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Hypertension Pink Sheet analysis
When running Hypertension Diagnostics' price analysis, check to measure Hypertension Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hypertension Diagnostics is operating at the current time. Most of Hypertension Diagnostics' value examination focuses on studying past and present price action to predict the probability of Hypertension Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hypertension Diagnostics' price. Additionally, you may evaluate how the addition of Hypertension Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |